Lab Manager | Run Your Lab Like a Business

Product News

New Fully Automated Single-Cell Dispenser for Microorganisms

B.SIGHTTM will reduce timelines and cut costs on single-cell microbiology research

Bacteria Lactobacillus in human intestine

CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows in Pharma and Biotech companies.

by
CYTENA

By providing the finest biosciences technologies to scientists and lab technicians around the world, CYTENA is creating the future of medicine. We aim to deliver automated and highly efficient lab...

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify
0:00
5:00

CYTENA, a BICO group company (Nasdaq Stockholm: BICO), a leading provider of high-precision instruments for handling biological cells, has launched a new instrument to streamline single-cell isolation in microbiology research. The next generation B.SIGHT is taking the company’s automated single-cell isolation capabilities to the next level with special emphasis on handling bacteria, yeast, and other microorganisms.

“The new B.SIGHT brings isolation of bacteria & yeast to the next level” said Dr. Julian Riba, CEO of CYTENA. “This second generation single-cell dispenser is really the outcome of a great collaboration between our team and our customers.”

For years, microbiologists have been interested in fully automating single-cell isolation from complex sample suspension in order to characterize unknown species. The new B.SIGHT has been designed to tackle this challenge efficiently and reliably. “The new instrument provides more automation, faster processing speeds, higher resolution, and precise dispensing,” said Dr. Hussein Hamzeh, the B.SIGHT’s Product Manager. Hamzeh also explained that, in addition to optimizing workflows, the B.SIGHT follows CYTENA’s philosophy on customer-conscious product design. “Researchers using the B.SIGHT not only will be able to accelerate microorganism isolation workflows but also significantly reduce plastic waste.”

CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows in Pharma and Biotech companies. It will also revolutionize the microbiome field by enabling scientists to streamline their microbiome work and accelerate their path towards transformative medicine. “We’re confident we can grow together with the customers who will introduce the B.SIGHT to their lab.” said Riba.